Molecular structure of Zanubrutinib, CAS Number: 1691249-45-2
Zanubrutinib (CAS 1691249-45-2)
Alternate Names:
(7S)-4,5,6,7-tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide, BGB-3111
CAS Number:
1691249-45-2
Molecular Weight:
471.6
Molecular Formula:
C27H29N5O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Zanubrutinib (CAS 1691249-45-2) References
- Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis. | Yin, S., et al. 2024. Ann Hematol. 103: 2231-2244. PMID: 37843620
- A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease. | Zhang, L., et al. 2024. Int J Hematol. 119: 631-637. PMID: 38546960
- New Means and Challenges in the Targeting of BTK. | Nawaratne, V., et al. 2024. Clin Cancer Res. 30: 2333-2341. PMID: 38578606
- Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL. | Gentile, G., et al. 2024. Blood Adv. 8: 2846-2860. PMID: 38598725
- An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. | Kittai, AS., et al. 2024. Blood Adv. 8: 2861-2869. PMID: 38598745
- Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. | Javidi-Sharifi, N. and Brown, JR. 2024. Expert Rev Hematol. 17: 201-210. PMID: 38784995
- Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon. | Lino-Silva, LS., et al. 2024. World J Clin Oncol. 15: 587-590. PMID: 38835851
- Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib. | Dostálová, H. and Kryštof, V. 2024. Hematol Oncol. 42: e3294. PMID: 38847437
- Current Approaches and Novel New Agents in the Treatment of Chronic Lymphocytic Leukemia. | Cheson, BD. and Sharman, JP. 2024. JCO Oncol Pract. OP2300770. PMID: 38848511
- Integrative bioinformatics approach for identifying key genes and potential therapeutic targets in the concurrent manifestation of hypertrophic cardiomyopathy and pulmonary hypertension. | Zheng, X., et al. 2024. J Thorac Dis. 16: 3152-3169. PMID: 38883633
- Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE. | Zhou, K., et al. 2024. Ann Hematol.. PMID: 38888616
- Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia. | Alsouqi, A. and Woyach, JA. 2024. Clin Lymphoma Myeloma Leuk.. PMID: 38897870
- A rare case of Richter transformation with breast involvement: A case report and literature review. | Wang, W., et al. 2024. Open Life Sci. 19: 20220889. PMID: 38911930
Inhibitor of:
3100002L24Rik, Btk, Gight chain, HACS1, IBtk, Ig λ, Ig λ chain, IgH, Igk-C, Olr1125, Olr113, Olr1245, Olr232, Olr307, Olr541, Olr655, Olr728, ROPN1, TNF receptor superfamily (TNFRSF), and VpreB1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Zanubrutinib, 5 mg | sc-507434 | 5 mg | $360.00 |